Equillium to Present EQ504 IL-10/IL-22 and Barrier Restoration Data at IMMUNOLOGY2026
Equillium will present new EQ504 preclinical data at IMMUNOLOGY2026 in Boston April 15-19, showcasing its potent AhR modulation and IL-10/IL-22 immune tolerance effects in two poster sessions. Presentations will detail cytokine release profiles and epithelial barrier restoration, underlining EQ504’s potential for ulcerative colitis and gastrointestinal disease therapies.
1. Poster Presentation Details
Equillium will feature two EQ504 poster presentations at IMMUNOLOGY2026 in Boston from April 15 to 19, 2026. The first session, ‘Immune Response Regulation: Cellular Mechanisms I’, runs April 16 with Poster Board 242 and a speaker slot at 2:30–3:30 PM EDT, focusing on IL-10 and IL-22 cytokine release. The second session, ‘Immunology of Barrier Surfaces’, occurs April 18 with Poster Board 517 and a speaker slot at 11:30 AM–12:30 PM EDT, comparing epithelial repair and barrier restoration versus validated AhR agonists.
2. EQ504 Mechanism and Therapeutic Potential
EQ504 is a selective aryl hydrocarbon receptor modulator designed for multi-modal, non-immunosuppressive action, supporting mucosal healing and immune regulation. Preclinical data highlight its promotion of immune tolerance and barrier function, positioning EQ504 as a candidate for enteric-coated delivery in ulcerative colitis and other gastrointestinal disorders, as well as inhaled formulations for inflammatory lung diseases.